Description: Chimeric Therapeutics Limited, a biotechnology company, develops and commercializes chimeric antigen receptor T cell therapy drugs for solid tumors in Australia. It is developing CLTX-CAR T cell therapy that is Phase I clinical study in Glioblastoma. The company was incorporated in 2020 and is based in Carlton South, Australia.
Home Page: www.chimerictherapeutics.com
CHM Technical Analysis
62 Lygon Street
Carlton,
VIC
3053
Australia
Phone:
61 3 9824 5254
Officers
| Name | Title |
|---|---|
| Ms. Jennifer Chow | CEO, MD & Director |
| Mr. Eliot Bourk | Chief Bus. Officer & Head of External Innovation |
| Dr. Li Ren | VP of Technical Operations |
| Mr. Kelly R. Thornburg | VP & Head of Quality |
| Mr. Jason B. Litten M.D. | Chief Medical Officer |
| Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBA | Sec. |
| Mr. Nathan Jong C.A. | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4172 |
| Price-to-Sales TTM: | 13.0917 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |